{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:39:55Z","timestamp":1787787595629,"version":"build-2784847793"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["\u201cRicerca Corrente\u201d"],"award-info":[{"award-number":["\u201cRicerca Corrente\u201d"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) remains one of the most frequently diagnosed malignancies in men globally, ranking second in prevalence, with increasing incidence anticipated due to aging populations. Radiotherapy has emerged as a cornerstone treatment for localized PCa with stereotactic body radiation therapy (SBRT), and it offers a promising approach by delivering highly conformal high-dose radiation in fewer fractions. This study compares the dosimetric outcomes of three SBRT techniques\u2014CyberKnife (CK), Volumetric Modulated Arc Therapy with flattening filter-free mode (VMAT FFF), and Helical Tomotherapy Radixact (HT)\u2014for localized PCa. The investigation evaluates dose distribution characteristics, sparing of organs at risk (OARs), and treatment delivery efficiency. Two patient groups with low-to-intermediate-risk localized PCa treated at the Istituto Nazionale Tumori\u2014IRCCS Fondazione G. Pascale were included. Treatment plans for CK, VMAT FFF, and HT were retrospectively generated and analyzed using dosimetric metrics such as Conformity Index (CI), Homogeneity Index (HI), Gradient Index, and dose\u2013volume constraints for OARs. Results revealed comparable target coverage across all techniques, with CK demonstrating superior dose conformity and VMAT FFF achieving shorter treatment times. HT and VMAT FFF are effective alternatives, particularly for centers without access to CK systems, though CK offered advantages in challenging anatomical scenarios. Findings emphasize the feasibility of VMAT FFF and HT as viable options for expanding SBRT accessibility, enabling high-quality treatment delivery in diverse clinical settings.<\/jats:p>","DOI":"10.1007\/s11547-025-02046-3","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:38:45Z","timestamp":1757572725000},"page":"1680-1692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating dosimetric outcomes: a comparison of CyberKnife, VMAT FFF, and Helical Tomotherapy Radixact for treating localized prostate cancer"],"prefix":"10.1007","volume":"130","author":[{"given":"Gaetano","family":"Gagliardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Ametrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Galiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Arrichiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Borzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Buonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"d\u2019Alesio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Di Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"2046_CR1","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F (2024) Global cancer observatory: cancer today, Lyon, France, 2024. https:\/\/gco.iarc.who.int\/today (accessed August 2, 2024)"},{"key":"2046_CR2","unstructured":"European Commission, Prostate cancer burden in EU-27, 2021. https:\/\/ecis.jrc.ec.europa.eu\/factsheets.php (accessed August 2, 2024)"},{"key":"2046_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ijc.29538","volume":"137","author":"KJL Bell","year":"2015","unstructured":"Bell KJL, Del Mar C, Wright G, Dickinson J, Glasziou P (2015) Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer 137:1749\u20131757. https:\/\/doi.org\/10.1002\/ijc.29538","journal-title":"Int J Cancer"},{"key":"2046_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63\u201389. https:\/\/doi.org\/10.14740\/wjon1191","journal-title":"World J Oncol"},{"key":"2046_CR5","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/cnr2.1764","volume":"6","author":"A Pulumati","year":"2023","unstructured":"Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RVL (2023) Technological advancements in cancer diagnostics: improvements and limitations. Cancer Rep 6:1764. https:\/\/doi.org\/10.1002\/cnr2.1764","journal-title":"Cancer Rep"},{"key":"2046_CR6","doi-asserted-by":"publisher","first-page":"14951","DOI":"10.1038\/s41598-024-65354-0","volume":"14","author":"H Sherafatmandjoo","year":"2024","unstructured":"Sherafatmandjoo H, Safaei AA, Ghaderi F, Allameh F (2024) Prostate cancer diagnosis based on multi-parametric MRI, clinical and pathological factors using deep learning. Sci Rep 14:14951. https:\/\/doi.org\/10.1038\/s41598-024-65354-0","journal-title":"Sci Rep"},{"key":"2046_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG (2021) Prostate cancer. Nat Rev Dis Primers 7:9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0","journal-title":"Nat Rev Dis Primers"},{"key":"2046_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","volume":"76","author":"TBL Lam","year":"2019","unstructured":"Lam TBL, MacLennan S, Willemse P-PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Colecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell\u2019Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Roupr\u00eat M, Rouvi\u00e8re O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N\u2019Dow JMO, Van Poppel H, Cornford P, Mottet N (2019) EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study). Eur Urol 76:790\u2013813. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.020","journal-title":"Eur Urol"},{"key":"2046_CR9","unstructured":"American Cancer Society, Treating Prostate Cancer, 2023. https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8796.00.pdf (accessed August 2, 2024)."},{"key":"2046_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","volume":"43","author":"DJ Brenner","year":"1999","unstructured":"Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Rad Oncol Biol Phys 43:1095\u20131101. https:\/\/doi.org\/10.1016\/S0360-3016(98)00438-6","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"2046_CR11","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 Patients in Seven International Institutional Datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) Gy. Int J Rad Oncol Biol Phys 82:e17\u2013e24. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.10.075","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"2046_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.rpor.2014.09.005","volume":"20","author":"F Alongi","year":"2015","unstructured":"Alongi F, Fiorentino A, De Bari B (2015) SBRT and extreme hypofractionation: a new era in prostate cancer treatments? Rep Pract Oncol Radiother 20:411\u2013416. https:\/\/doi.org\/10.1016\/j.rpor.2014.09.005","journal-title":"Rep Pract Oncol Radiother"},{"key":"2046_CR13","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.3390\/cancers15143659","volume":"15","author":"J Pardo-Montero","year":"2023","unstructured":"Pardo-Montero J, Gonz\u00e1lez-Crespo I, G\u00f3mez-Caama\u00f1o A, Gago-Arias A (2023) Radiobiological Meta-analysis of the response of prostate cancer to different fractionations: evaluation of the linear-quadratic response at large doses and the effect of risk and ADT. Cancers 15:3659. https:\/\/doi.org\/10.3390\/cancers15143659","journal-title":"Cancers"},{"key":"2046_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","volume":"8","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H (2018) Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline, Pract. Radiat Oncol 8:354\u2013360. https:\/\/doi.org\/10.1016\/j.prro.2018.08.002","journal-title":"Radiat Oncol"},{"key":"2046_CR15","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N, Dodds D, Lartigau E, Patton S, Thompson A, Winkler M, Wells P, Lymberiou T, Saunders D, Vilarino-Varela M, Vavassis P, Tsakiridis T, Carlson R, Rodrigues G, Tanguay J, Iqbal S, Winkler M, Morgan S, Mihai A, Li A, Din O, Panades M, Wade R, Rimmer Y, Armstrong J, Panades M, Oommen N (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20:1531\u20131543. https:\/\/doi.org\/10.1016\/S1470-2045(19)30569-8","journal-title":"Lancet Oncol"},{"key":"2046_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","volume":"22","author":"P Fransson","year":"2021","unstructured":"Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Bj\u00f6rnlinger K, Seke M, Agrup M, Zackrisson B, Kjell\u00e9n E, Franz\u00e9n L, Widmark A (2021) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 22:235\u2013245. https:\/\/doi.org\/10.1016\/S1470-2045(20)30581-7","journal-title":"Lancet Oncol"},{"key":"2046_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023574","volume":"99","author":"M Serra","year":"2020","unstructured":"Serra M, Ametrano G, Borzillo V, Quarto M, Muto M, Di Franco R, Federica S, Loffredo F, Paolo M (2020) Dosimetric comparison among cyberknife, helical tomotherapy and VMAT for hypofractionated treatment in localized prostate cancer. Medicine 99:e23574. https:\/\/doi.org\/10.1097\/MD.0000000000023574","journal-title":"Medicine"},{"key":"2046_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3390\/life12050711","volume":"12","author":"M Serra","year":"2022","unstructured":"Serra M, De Martino F, Savino F, D\u2019Alesio V, Arrichiello C, Quarto M, Loffredo F, Di Franco R, Borzillo V, Muto M, Ametrano G, Muto P (2022) SBRT for Localized Prostate Cancer: CyberKnife vs. VMAT-FFF, a Dosimetric Study, Life 12:711. https:\/\/doi.org\/10.3390\/life12050711","journal-title":"VMAT-FFF, a Dosimetric Study, Life"},{"key":"2046_CR19","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/cancers14133187","volume":"14","author":"R Di Franco","year":"2022","unstructured":"Di Franco R, Borzillo V, Scipilliti E, Ametrano G, Serra M, Arrichiello C, Savino F, De Martino F, D\u2019Alesio V, Cammarota F, Crispo A, Pignata S, Rossetti S, Quarto G, Muto P (2022) Reirradiation of locally recurrent prostate cancer with Cyberknife\u00ae system or volumetric modulated arc therapy (VMAT) and IGRT-Clarity\u00ae: outcomes, toxicities and dosimetric evaluation. Cancers 14:3187. https:\/\/doi.org\/10.3390\/cancers14133187","journal-title":"Cancers"},{"key":"2046_CR20","doi-asserted-by":"publisher","first-page":"1270498","DOI":"10.3389\/fonc.2023.1270498","volume":"13","author":"V Borzillo","year":"2023","unstructured":"Borzillo V, Scipilliti E, Pezzulla D, Serra M, Ametrano G, Quarto G, Perdon\u00e0 S, Rossetti S, Pignata S, Crispo A, Di Gennaro P, D\u2019Alesio V, Arrichiello C, Buonanno F, Mercogliano S, Russo A, Tufano A, Di Franco R, Muto P (2023) Stereotactic body radiotherapy with CyberKnife\u00ae System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial. Front Oncol 13:1270498. https:\/\/doi.org\/10.3389\/fonc.2023.1270498","journal-title":"Front Oncol"},{"key":"2046_CR21","unstructured":"Accuray Incorporated, Brochure Equipment Specifications - CyberKnife., n.d. https:\/\/www.cyberknifelatin.com\/pdf\/brochure-tecnico.pdf (accessed August 5, 2024)"},{"key":"2046_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1120\/jacmp.v15i1.4095","volume":"15","author":"TT Sio","year":"2014","unstructured":"Sio TT, Jang S, Lee S, Curran B, Pyakuryal AP, Sternick ES (2014) Comparing Gamma Knife and CyberKnife in patients with brain metastases. J Appl Clin Med Phys 15:14\u201326. https:\/\/doi.org\/10.1120\/jacmp.v15i1.4095","journal-title":"J Appl Clin Med Phys"},{"key":"2046_CR23","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160296","author":"AGM O\u2019Neill","year":"2016","unstructured":"O\u2019Neill AGM, Jain S, Hounsell AR, O\u2019Sullivan JM (2016) Fiducial marker guided prostate radiotherapy: a review. Br J Radiol. https:\/\/doi.org\/10.1259\/bjr.20160296","journal-title":"Br J Radiol"},{"key":"2046_CR24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.21037\/tau.2017.12.37","volume":"7","author":"A Dang","year":"2018","unstructured":"Dang A, Kupelian PA, Cao M, Agazaryan N, Kishan AU (2018) Image-guided radiotherapy for prostate cancer. Transl Androl Urol 7:308\u2013320. https:\/\/doi.org\/10.21037\/tau.2017.12.37","journal-title":"Transl Androl Urol"},{"key":"2046_CR25","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.21873\/invivo.12447","volume":"35","author":"R Di Franco","year":"2021","unstructured":"Di Franco R, Borzillo V, Alberti D, Ametrano G, Petito A, Coppolaro A, Tarantino I, Rossetti S, Pignata S, Iovane G, Perdon\u00e0 S, Quarto G, Grimaldi G, Izzo A, Castaldo L, Muscariello R, Serra M, Facchini G, Muto P (2021) Acute Toxicity in hypofractionated\/stereotactic prostate radiotherapy of elderly patients: use of the image-guided radio therapy (IGRT) clarity system. In Vivo (Brooklyn) 35:1849\u20131856. https:\/\/doi.org\/10.21873\/invivo.12447","journal-title":"In Vivo (Brooklyn)"},{"key":"2046_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.radonc.2020.04.037","volume":"148","author":"EJ Lehrer","year":"2020","unstructured":"Lehrer EJ, Kishan AU, Yu JB, Trifiletti DM, Showalter TN, Ellis R, Zaorsky NG (2020) Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: a systematic review and meta-analysis of phase III randomized trials. Radiother Oncol 148:235\u2013242. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.037","journal-title":"Radiother Oncol"},{"key":"2046_CR27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.31557\/APJCP.2020.21.4.1149","volume":"21","author":"TK Bijina","year":"2020","unstructured":"Bijina TK, Ganesh KM, Pichandi A, Muthuselvi CA (2020) Cyberknife, helical tomotherapy and rapid arc SIB-SBRT treatment plan comparison for carcinoma prostate. Asian Pacific J Canc Prevent 21:1149\u20131154. https:\/\/doi.org\/10.31557\/APJCP.2020.21.4.1149","journal-title":"Asian Pacific J Canc Prevent"},{"key":"2046_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00066-020-01723-8","volume":"197","author":"F Wolf","year":"2021","unstructured":"Wolf F, Sedlmayer F, Aebersold D, Albrecht C, B\u00f6hmer D, Flentje M, Ganswindt U, Ghadjar P, H\u00f6cht S, H\u00f6lscher T, M\u00fcller A-C, Niehoff P, Pinkawa M, Schmidt-Hegemann N-S, Zamboglou C, Zips D, Wiegel T (2021) Ultrahypofractionation of localized prostate cancer. Strahlenther Onkol 197:89\u201396. https:\/\/doi.org\/10.1007\/s00066-020-01723-8","journal-title":"Strahlenther Onkol"},{"key":"2046_CR29","doi-asserted-by":"publisher","first-page":"110617","DOI":"10.1016\/j.apradiso.2022.110617","volume":"192","author":"AM \u015eeni\u015fik","year":"2023","unstructured":"\u015eeni\u015fik AM, Okutan M, \u00c7akir A, Iriba\u015f \u00c7elik A, Kaytan Sa\u011flam E, \u00c7evikba\u015f G, Demir B (2023) A dosimetric comparison for SBRT plans of localized prostate cancer between Cyberknife and Varian Truebeam STX device. Appl Rad Isotop 192:110617. https:\/\/doi.org\/10.1016\/j.apradiso.2022.110617","journal-title":"Appl Rad Isotop"},{"key":"2046_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100779","volume":"46","author":"M Galienne","year":"2024","unstructured":"Galienne M, Risbourg S, Lacornerie T, Taillez A, Lartigau E, Barthoulot M, Pasquier D (2024) Extreme hypofractionated stereotactic radiotherapy for localized prostate Cancer: efficacy and late urinary toxicity according to transurethral resection of the prostate history. Clin Transl Radiat Oncol 46:100779. https:\/\/doi.org\/10.1016\/j.ctro.2024.100779","journal-title":"Clin Transl Radiat Oncol"},{"key":"2046_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1118\/1.2818738","volume":"35","author":"K Otto","year":"2008","unstructured":"Otto K (2008) Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 35:310\u2013317. https:\/\/doi.org\/10.1118\/1.2818738","journal-title":"Med Phys"},{"key":"2046_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejmp.2012.10.003","volume":"30","author":"C Lafond","year":"2014","unstructured":"Lafond C, Gassa F, Odin C, Dr\u00e9an G, Even J, De Crevoisier R, Pommier P, Manens J-P, Biston M-C (2014) Comparison between two treatment planning systems for volumetric modulated arc therapy optimization for prostate cancer. Physica Med 30:2\u20139. https:\/\/doi.org\/10.1016\/j.ejmp.2012.10.003","journal-title":"Physica Med"},{"key":"2046_CR33","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1088\/0031-9155\/40\/9\/004","volume":"40","author":"CX Yu","year":"1995","unstructured":"Yu CX (1995) Intensity-modulated arc therapy with dynamic multileaf collimation: an alternative to tomotherapy. Phys Med Biol 40:1435\u20131449. https:\/\/doi.org\/10.1088\/0031-9155\/40\/9\/004","journal-title":"Phys Med Biol"},{"key":"2046_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0360-3016(02)02777-36","volume":"53","author":"CX Yu","year":"2002","unstructured":"Yu CX, Li XA, Ma L, Chen D, Naqvi S, Shepard D, Sarfaraz M, Holmes TW, Suntharalingam M, Mansfield CM (2002) Clinical implementation of intensity-modulated arc therapy. Int J Rad Oncol Biol Phys 53:453\u2013463. https:\/\/doi.org\/10.1016\/S0360-3016(02)02777-36","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"2046_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2011.01.011","volume":"81","author":"CF Njeh","year":"2012","unstructured":"Njeh CF, Saunders MW, Langton CM (2012) Accelerated partial breast irradiation using external beam conformal radiation therapy: A review. Crit Rev Oncol Hematol 81:1\u201320. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.01.011","journal-title":"Crit Rev Oncol Hematol"},{"key":"2046_CR36","first-page":"55","volume":"1","author":"M Lachaine","year":"2013","unstructured":"Lachaine M, Falco T (2013) Intrafractional prostate motion management with the clarity autoscan system. Med Phys Int J 1:55","journal-title":"Med Phys Int J"},{"key":"2046_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.radonc.2020.04.044","volume":"149","author":"A Grimwood","year":"2020","unstructured":"Grimwood A, Rivaz H, Zhou H, McNair HA, Jakubowski K, Bamber JC, Tree AC, Harris EJ (2020) Improving 3D ultrasound prostate localisation in radiotherapy through increased automation of interfraction matching. Radiother Oncol 149:134\u2013141. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.044","journal-title":"Radiother Oncol"},{"key":"2046_CR38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/HP.0000000000001524","volume":"122","author":"M Buono","year":"2022","unstructured":"Buono M, Capussela T, Loffredo F, Di Pasquale MA, Serra M, Quarto M (2022) Dose-tracking software: a retrospective analysis of dosimetric data in CT procedures. Health Phys 122:548\u2013555. https:\/\/doi.org\/10.1097\/HP.0000000000001524","journal-title":"Health Phys"},{"key":"2046_CR39","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00432-014-1732-1","volume":"140","author":"M Scorsetti","year":"2014","unstructured":"Scorsetti M, Alongi F, Clerici E, Comito T, Fogliata A, Iftode C, Mancosu P, Navarria P, Reggiori G, Tomatis S, Villa E, Cozzi L (2014) Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. J Cancer Res Clin Oncol 140:1795\u20131800. https:\/\/doi.org\/10.1007\/s00432-014-1732-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"2046_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/153303460200100413","volume":"1","author":"JS Welsh","year":"2002","unstructured":"Welsh JS, Patel RR, Ritter MA, Harari PM, Mackie TR, Mehta MP (2002) Helical tomotherapy: an innovative technology and approach to radiation therapy. Technol Cancer Res Treat 1:311\u2013316. https:\/\/doi.org\/10.1177\/153303460200100413","journal-title":"Technol Cancer Res Treat"},{"key":"2046_CR41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30949","author":"H Kurosaki","year":"2022","unstructured":"Kurosaki H, Hirayama K, Takahashi M, Uematsu M, Tate E (2022) Tomotherapy: comparison of Hi-ART, Tomo-HD, and Radixact. Cureus. https:\/\/doi.org\/10.7759\/cureus.30949","journal-title":"Cureus"},{"key":"2046_CR42","doi-asserted-by":"publisher","first-page":"13648","DOI":"10.1002\/acm2.13648","volume":"23","author":"RC Tegtmeier","year":"2022","unstructured":"Tegtmeier RC, Ferris WS, Bayouth JE, Miller JR, Culberson WS (2022) Characterization of imaging performance of a novel helical kVCT for use in image-guided and adaptive radiotherapy. J Appl Clin Med Phys 23:13648. https:\/\/doi.org\/10.1002\/acm2.13648","journal-title":"J Appl Clin Med Phys"},{"key":"2046_CR43","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969. https:\/\/doi.org\/10.1001\/jama.280.11.969","journal-title":"JAMA"},{"key":"2046_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ctrv.2016.08.005","volume":"50","author":"B De Bari","year":"2016","unstructured":"De Bari B, Arcangeli S, Ciardo D, Mazzola R, Alongi F, Russi EG, Santoni R, Magrini SM, Jereczek-Fossa BA (2016) Extreme hypofractionation for early prostate cancer: biology meets technology. Cancer Treat Rev 50:48\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.08.005","journal-title":"Cancer Treat Rev"},{"key":"2046_CR45","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1259\/bjr\/36606138","volume":"85","author":"K Ohtakara","year":"2012","unstructured":"Ohtakara K, Hayashi S, Hoshi H (2012) The relation between various conformity indices and the influence of the target coverage difference in prescription isodose surface on these values in intracranial stereotactic radiosurgery. Br J Radiol 85:e223\u2013e228. https:\/\/doi.org\/10.1259\/bjr\/36606138","journal-title":"Br J Radiol"},{"key":"2046_CR46","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/0360-3016(93)90548-A","volume":"27","author":"E Shaw","year":"1993","unstructured":"Shaw E, Kline R, Gillin M, Souhami L, Hirschfeld A, Dinapoli R, Martin L (1993) Radiation therapy oncology group: radiosurgery quality assurance guidelines. Int J Rad Oncol Biol Phys 27:1231\u20131239. https:\/\/doi.org\/10.1016\/0360-3016(93)90548-A","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"2046_CR47","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.rpor.2020.03.002","volume":"25","author":"G Patel","year":"2020","unstructured":"Patel G, Mandal A, Choudhary S, Mishra R, Shende R (2020) Plan evaluation indices: a journey of evolution. Rep Pract Oncol Radiother 25:336\u2013344. https:\/\/doi.org\/10.1016\/j.rpor.2020.03.002","journal-title":"Rep Pract Oncol Radiother"},{"key":"2046_CR48","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3171\/sup.2006.105.7.194","volume":"105","author":"I Paddick","year":"2006","unstructured":"Paddick I, Lippitz B (2006) A simple dose gradient measurement tool to complement the conformity index. J Neurosurg 105:194\u2013201. https:\/\/doi.org\/10.3171\/sup.2006.105.7.194","journal-title":"J Neurosurg"},{"key":"2046_CR49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3171\/2014.7.GKS141199","volume":"121","author":"M Torrens","year":"2014","unstructured":"Torrens M, Chung C, Chung H-T, Hanssens P, Jaffray D, Kemeny A, Larson D, Levivier M, Lindquist C, Lippitz B, Novotny J, Paddick I, Prasad D, Yu CP (2014) Standardization of terminology in stereotactic radiosurgery: report from the standardization committee of the international Leksell Gamma Knife Society. J Neurosurg 121:2\u201315. https:\/\/doi.org\/10.3171\/2014.7.GKS141199","journal-title":"J Neurosurg"},{"key":"2046_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13014-019-1353-6","volume":"14","author":"S Scobioala","year":"2019","unstructured":"Scobioala S, Kittel C, Elsayad K, Kroeger K, Oertel M, Samhouri L, Haverkamp U, Eich HT (2019) A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma. Radiat Oncol 14:143. https:\/\/doi.org\/10.1186\/s13014-019-1353-6","journal-title":"Radiat Oncol"},{"key":"2046_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1533034616682156","volume":"16","author":"J Sepp\u00e4l\u00e4","year":"2017","unstructured":"Sepp\u00e4l\u00e4 J, Suilamo S, Tenhunen M, Sailas L, Virsunen H, Kaleva E, Keyril\u00e4inen J (2017) Dosimetric comparison and evaluation of 4 stereotactic body radiotherapy techniques for the treatment of prostate cancer. Technol Cancer Res Treat 16:238\u2013245. https:\/\/doi.org\/10.1177\/1533034616682156","journal-title":"Technol Cancer Res Treat"},{"key":"2046_CR52","doi-asserted-by":"publisher","first-page":"L41","DOI":"10.1088\/1361-6560\/aa9517","volume":"62","author":"BW Raaymakers","year":"2017","unstructured":"Raaymakers BW, J\u00fcrgenliemk-Schulz IM, Bol GH, Glitzner M, Kotte ANTJ, Van Asselen B, De Boer JCJ, Bluemink JJ, Hackett SL, Moerland MA, Woodings SJ, Wolthaus JWH, Van Zijp HM, Philippens MEP, Tijssen R, Kok JGM, De Groot-Van Breugel EN, Kiekebosch I, Meijers LTC, Nomden CN, Sikkes GG, Doornaert PAH, Eppinga WSC, Kasperts N, Kerkmeijer LGW, Tersteeg JHA, Brown KJ, Pais B, Woodhead P, Lagendijk JJW (2017) First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. Phys Med Biol 62:L41\u2013L50. https:\/\/doi.org\/10.1088\/1361-6560\/aa9517","journal-title":"Phys Med Biol"},{"key":"2046_CR53","doi-asserted-by":"publisher","first-page":"1117874","DOI":"10.3389\/fonc.2023.1117874","volume":"13","author":"J Ng","year":"2023","unstructured":"Ng J, Gregucci F, Pennell RT, Nagar H, Golden EB, Knisely JPS, Sanfilippo NJ, Formenti SC (2023) MRI-LINAC: a transformative technology in radiation oncology. Front Oncol 13:1117874. https:\/\/doi.org\/10.3389\/fonc.2023.1117874","journal-title":"Front Oncol"},{"key":"2046_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","volume":"15","author":"F Alongi","year":"2020","unstructured":"Alongi F, Rigo M, Figlia V, Cuccia F, Giaj-Levra N, Nicosia L, Ricchetti F, Sicignano G, De Simone A, Naccarato S, Ruggieri R, Mazzola R (2020) 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Rad Oncol 15:69. https:\/\/doi.org\/10.1186\/s13014-020-01510-w","journal-title":"Rad Oncol"},{"key":"2046_CR55","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3390\/curroncol31050203","volume":"31","author":"V Potkrajcic","year":"2024","unstructured":"Potkrajcic V, Gani C, Fischer SG, Boeke S, Niyazi M, Thorwarth D, Voigt O, Schneider M, M\u00f6nnich D, K\u00fcbler S, Boldt J, Hoffmann E, Paulsen F, Mueller A-C, Wegener D (2024) Online adaptive MR-guided ultrahypofractionated radiotherapy of prostate cancer on a 15 T MR-Linac: clinical experience and prospective evaluation. Curr Oncol 31:2679\u20132688. https:\/\/doi.org\/10.3390\/curroncol31050203","journal-title":"Curr Oncol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02046-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-025-02046-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02046-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:25:33Z","timestamp":1761132333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-025-02046-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["2046"],"URL":"https:\/\/doi.org\/10.1007\/s11547-025-02046-3","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. This study complies with all ethical principles and does not contravene any ethical guidelines. This study is part of the Cypro Trial, approved by the Ethics committee of the National Cancer Institute\u2014G. Pascale Foundation\u2014Naples, Protocol Version 1.0; 27th of January 2020. Decision n\u00b0 105.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}